Warren Greth

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth et al. · Annals of the Rheumatic Diseases · 2016 · 498 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Michelle Petri, Daniel J. Wallace, Alberto Spindler et al. · Arthritis & Rheumatism · 2013 · 240 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Brandon W. Higgs, Wei Zhu, Chris Morehouse et al. · Annals of the Rheumatic Diseases · 2013 · 166 citations · Full text

Life Sciences, Immunology, Pharmacology +13

Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population

D.E. Furst, AE Clarke, AW Fernandes et al. · Lupus · 2012 · 69 citations

Veterinary Medicine, Internal Medicine, Epidemiology +11

Epidemiology of Systemic Sclerosis in a Large US Managed Care Population

Daniel E. Fürst, Ancilla W. Fernandes, Şerban R. Iorga et al. · The Journal of Rheumatology · 2012 · 55 citations

Medicine, Health Services Administration, Clinical Epidemiology +8